Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
OBJECTIVE
To investigate the effectiveness of 4 d' anti-Helicobacter pylori therapy on the H pylori-infected Mongolian gerbils based on physiological and pathological changes.


METHODS
We used 6-wk-old male gerbils orally inoculated with H pylori (ATCC43504, 2X10(8) CFU/mL). Seven weeks after H pylori inoculation, the animals of study group received 4 d' anti-H pylori triple therapy (H pylori-eradicated group). Seven days later, all animals of the H pylori-eradicated and control groups (H pylori-infected and H pylori-uninfected groups) were sacrificed. We examined gastric mucosal lesions macroscopically, studied gastritis microscopically and determined the stomach weight ratio, myeloperoxidase (MPO) activity and prostaglandin (PG) E(2) level.


RESULTS
The results showed that both macroscopic and histological gastric damages were significantly less in H pylori-eradicated group than H pylori-infected group. Stomach weight ratio, MPO activity and PGE(2) levels were significantly higher in H pylori-infected group than those in the other two groups.


CONCLUSIONS
Four days' anti-H pylori therapy was effective in the improvement of H pylori-induced gastric lesions in Mongolian gerbils.
Chang
Chun-Chao
CC
Department of Internal Medicine, Taipei Medical University Hospital, No. 252, Wu-Hsing Street, Taipei 110, Taiwan, China. chunchao@tmu.edu.tw
Chen
Sheng-Hsuan
SH
Lien
Gi-Shih
GS
Lee
Yuarn-Jang
YJ
Lou
Horng-Yuan
HY
Hsieh
Ching-Ruey
CR
Fang
Chia-Lang
CL
Pan
Shiann
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D005849:Gerbillinae; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole
J Gastroenterol Hepatol. 1999 Nov;14(11):1062-9
10574132
Dig Dis Sci. 1999 Feb;44(2):257-65
10063909
Eur J Pharmacol. 2000 Oct 20;406(3):461-8
11040354
Lancet. 1983 Jun 4;1(8336):1273-5
6134060
N Engl J Med. 1993 Feb 4;328(5):308-12
8419816
Dig Dis Sci. 1998 Apr;43(4):754-65
9558031
Jpn J Cancer Res. 2000 Aug;91(8):769-73
10965015
JAMA. 1994 Jul 6;272(1):65-9
8007082
Gastroenterology. 1994 Dec;107(6):1746-50
7958687
J Clin Gastroenterol. 1998;27 Suppl 1:S141-3
9872511
J Gastroenterol. 1996 Oct;31(5):755-7
8887049
J Gastroenterol. 1998 Feb;33(1):14-7
9497215
Gastroenterology. 1988 Jan;94(1):33-40
3335295
IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
7715068
N Engl J Med. 1991 Oct 17;325(16):1127-31
1891020
J Gastroenterol. 1996 Nov;31 Suppl 9:24-8
8959513